Rilonacept + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cold Contact Urticaria

Conditions

Cold Contact Urticaria

Trial Timeline

Jan 1, 2015 → May 1, 2018

NCT ID

NCT02171416

About Rilonacept + Placebo

Rilonacept + Placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Cold Contact Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT02171416. Target conditions include Cold Contact Urticaria.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02171416	Phase 2	Completed	Jan 1, 2015	May 1, 2018	Cold Contact Urticaria

Competing Products

20 competing products in Cold Contact Urticaria

See all competitors

Product	Company	Stage	Hype Score
THB001	Third Harmonic Bio	Phase 1	25
Nasal Glucagon + Oxymetazoline	Eli Lilly	Phase 1	33
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo	Johnson & Johnson	Phase 2	52
Pseudoephedrine/Paracetamol	Johnson & Johnson	Approved	85
DFV890	Novartis	Phase 2	52
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg	Novartis	Phase 3	77
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	52
Dextromethorphan + Placebo	Novartis	Approved	85
Xylometazoline	Novartis	Phase 3	77
Penciclovir + Placebo	Novartis	Approved	85
N-acetylcysteine + Placebo	Novartis	Phase 2	52
Advil Congestion Relief + Advil Allergy and Congestion Relief + Paracetamol	Pfizer	Phase 3	76
pseudoephedrine hydrochloride 30 mg tablets + Placebo tablets	Pfizer	Phase 3	76
Pegcetacoplan + Placebo matching Pegcetacoplan	Swedish Orphan Biovitrum	Phase 3	76
sutimlimab	Sanofi	Phase 3	76
sutimlimab (BIVV009) + placebo	Sanofi	Phase 3	76
Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamine	Sanofi	Phase 3	76
BIVV009	Sanofi	Phase 3	76
rilonacept 160 mg + Placebo + rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	76
HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 Placebo	Haisco Pharmaceutical Group	Phase 2	49

Other Products from Regeneron Pharmaceuticals

DupilumabApproved

Intravitreal Aflibercept Injection 2mgApproved

Intravitreal aflibercept injection 2.0mgApproved

PozelimabApproved

DupilumabApproved